Related Experiment Video

Updated: Feb 20, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.4K

EGFR T790M: revealing the secrets of a gatekeeper

Brian Ko1, Daniel Paucar1, Balazs Halmos1

  • 1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.

Lung Cancer (Auckland, N.Z.)
|October 27, 2017
PubMed

Insights

EGFR T790M mutations cause resistance to lung cancer TKIs. New third-generation TKIs show promise in overcoming this resistance, offering hope for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Activating mutations in the Epidermal Growth Factor Receptor (EGFR) gene define a key subset of non-small-cell lung cancers.
  • First- and second-generation EGFR tyrosine-kinase inhibitors (TKIs) initially show efficacy but are often limited by acquired resistance.

Purpose of the Study:

  • To review the mechanisms of EGFR T790M-mediated resistance in non-small-cell lung cancer.
  • To discuss the development and efficacy of third-generation EGFR TKIs targeting EGFR T790M.
  • To highlight ongoing research into overcoming resistance to third-generation EGFR TKIs.

Main Methods:

  • Literature review of studies on EGFR mutations, TKI resistance mechanisms, and novel therapeutic strategies.
  • Analysis of preclinical and clinical data for third-generation EGFR TKIs.
  • Synthesis of current research findings on overcoming resistance to targeted therapies.

Main Results:

  • The T790M amino acid substitution in EGFR is a prevalent gatekeeper mutation conferring resistance to earlier TKIs.
  • Novel third-generation EGFR TKIs demonstrate activity against EGFR T790M mutations.
  • Emerging research is exploring strategies to circumvent resistance to third-generation TKIs.

Conclusions:

  • EGFR T790M mutations are a critical challenge in EGFR-mutant non-small-cell lung cancer treatment.
  • Third-generation EGFR TKIs represent a significant advancement in targeting resistant tumors.
  • Further research is essential to address and overcome resistance to current and future targeted therapies.
Keywords:
T790Mepidermal growth factor receptorlung cancerresistancetargeted therapy

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.5K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K